Inclisiran First Strategy Safe, Effective for LDL-C Control in ASCVD Patients
HCPLive
APRIL 6, 2024
New data from a phase 3b trial presented at ACC.24 underlines the potential of inclisiran in reducing LDL-C levels among patients with ASCVD.
Sat.Apr 06, 2024
124 
A young woman with chest pain, cath lab activated
Dr. Smith's ECG Blog
APRIL 6, 2024
This case came from a friend whose sister was the patient. She knew I was interested in ECGs, so she took a photo of this one. A young woman presented with acute chest pain. This was her presenting ECG: What do you think? This is clearly Brugada phenotype. There is downsloping ST Elevation in V1 and V2. To an experienced interpreter, it is clearly not due to OMI.
No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1, A Building Block of HDL Cholesterol
DAIC
APRIL 6, 2024
milla1cf Sat, 04/06/2024 - 18:32 April 6, 2024 — The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heart attack or stroke within three months of a prior heart attack, according to research presented at the American College of Cardiology ’s Annual Scientific Session. However, the findings suggest that the strategy may be beneficial with longer follow-up.
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
JAMA Cardiology
APRIL 6, 2024
This randomized clinical trial assesses the safety and effectiveness of plozasiran, an investigational APOC3-targeted drug, in the reduction of serum triglyceride level in patients with severe hypertriglyceridemia.
SGLT-2 Inhibitors Show Mixed Results After Heart Attack
DAIC
APRIL 6, 2024
milla1cf Sat, 04/06/2024 - 18:48 April 6, 2024 — Use of the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin following a heart attack did not show a significant benefit in reducing overall heart failure hospitalizations or death from any cause, according to a study presented at the American College of Cardiology ’s Annual Scientific Session.
Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease
JAMA Cardiology
APRIL 6, 2024
This secondary analysis of a randomized clinical trial examines the antibody response to high-dose trivalent compared with standard-dose quadrivalent inactivated influenza vaccine in patients with a recent acute myocardial infarction or heart failure hospitalization.
EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack
DAIC
APRIL 6, 2024
While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24, being held in Atlanta, GA. milla1cf Sat, 04/06/2024 - 18:48 April 6, 2024 — Use of the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin following a heart attack did not show a significant
Sign up to get articles personalized to your interests!
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
More Trending
RELIEVE-HF Trial Outcomes Reported at ACC.24 Find Impact of Interatrial Shunt May Vary by Heart Failure Type
DAIC
APRIL 6, 2024
Patients with heart failure who had a small shunt inserted between the heart’s left and right atria did not see any significant benefits overall compared with those who received a placebo procedure after a median of 22 months follow-up, according to a study presented during the first day of the American College of Cardiology Scientific Sessions, ACC.24, in Atlanta, GA. milla1cf Sat, 04/06/2024 - 19:08 April 6, 2024 — Patients with heart failure who had a small shunt inserted between the heart’s
EMPACT-MI: Empagliflozin Post MI Does Not Lower Risk of First HF Hospitalization, Death
American College of Cardiology
APRIL 6, 2024
The SGLT2 inhibitor empagliflozin did not lower the risk of a first hospitalization for heart failure (HF) or death from any cause among patients with an increased risk for HF following acute myocardial infarction (MI), according to the results of the EMPACT-MI study, presented during a Late-Breaking Clinical Trial session at ACC.24 and published simultaneously in the New England Journal of Medicine.
Research Presented at ACC 2024 Found No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1
DAIC
APRIL 6, 2024
The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the risk of death, heart attack or stroke within three months of a prior heart attack, according to research presented at ACC.24, the American College of Cardiology Annual Annual Scientific Session. The findings, however, suggest that the strategy may be beneficial with longer follow-up. milla1cf Sat, 04/06/2024 - 18:32 April 6, 2024 — The first trial of a novel strategy for removing cholesterol f
Routine Beta-Blockers in Secondary Prevention — On Injured Reserve
The New England Journal of Medicine
APRIL 6, 2024
The benefit of beta-blockers after myocardial infarction was established before the advent of reperfusion and percutaneous coronary intervention and the availability of effective secondary preventive medications.1-3 Since these other treatments became accessible, the value of beta-blocker therapy in patients with coronary artery disease or myocardial infarction but without.
Impact of Interatrial Shunt May Vary by Heart Failure Type
DAIC
APRIL 6, 2024
milla1cf Sat, 04/06/2024 - 19:08 April 6, 2024 — Patients with heart failure who had a small shunt inserted between the heart’s left and right atria did not see any significant benefits overall compared with those who received a placebo procedure after a median of 22 months follow-up, in a study presented at the American College of Cardiology ’s Annual Scientific Session.
VICTORION-INITIATE: "Inclisiran-First" Strategy Yields Greater LDL-C Reduction
American College of Cardiology
APRIL 6, 2024
In patients with atherosclerotic cardiovascular disease (ASCVD) who have not reached LDL-C levels <70 mg/dL,immediately adding inclisiran led to greater reductions in LDL-C, according to results of the open-label, Phase 3b VICTORION-INITIATE study presented during a Featured Clinical Research session.
Empagliflozin Misses Primary Endpoint in Post-MI Patient Population, EMPACT-MI Trial
HCPLive
APRIL 6, 2024
Results of EMPACT-MI suggest use of empagliflozin was not associated with a statistically significant reduction in a composite of death and heart failure hospitalization.
Comparison of an “Inclisiran First� Strategy With Usual Care in Patients With Atherosclerotic Cardiovascular Disease
American College of Cardiology
APRIL 6, 2024
The goal of the VICTORION-INITIATE trial was to determine the effect of adding inclisiran, a small interfering RNA targeting hepatic PCSK9, versus usual care in achieving adequate lipid lowering in patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statin therapy or with statin intolerance.
AEGIS-II Misses Primary Endpoint, Suggests Potential for CSL112 in Hyperlipidemia
HCPLive
APRIL 6, 2024
CSL112 infusion did not reduce major cardiovascular events at 90 days but further analysis suggests patients with elevated LDL-C levels could derive significant benefit.
Semaglutide Treatment Effect in People With Obesity and Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus
American College of Cardiology
APRIL 6, 2024
The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).
Can Machine Learning Predict CVD Risk? Sleep-Related Benefits of Exercise
Med Page Today
APRIL 6, 2024
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center.
AEGIS-II: CSL112 Associated With Lower Rates of CV Death, MI
American College of Cardiology
APRIL 6, 2024
Intravenous infusions of CSL112, human plasma-derived apolipoprotein A-I (apoA-I), were associated with numerically lower rates of cardiovascular death and myocardial infarction (MI), according to the AEGIS-II study presented during a Late-Breaking Clinical Trial session at ACC.24 in Atlanta and simultaneously published in the New England Journal of Medicine.
Research Data from Minneapolis Heart Institute Foundation at ACC 2024 Reveal Trends in Cardiovascular Risk Factors and Preventive Medication Use Prior to Heart Attacks
DAIC
APRIL 6, 2024
The Minneapolis Heart Institute Foundation (MHIF) is presenting leading research focused on trends in ST-elevation myocardial infarction (STEMI), the most severe form of a heart attack, at the American College of Cardiology’s Annual Scientific Session (ACC.24), being held April 6-8 in Atltanta, GA. An analysis of nearly 8,000 STEMI patients over 20 years found the majority of STEMI occur in individuals without prior cardiovascular disease, and this prevalence is unchanged over time.
Study to Evaluate the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients With Acute Myocardial Infarction
American College of Cardiology
APRIL 6, 2024
The goal of the EMPACT-MI trial was to determine whether adding the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin to the treatment of acute myocardial infarction (AMI) affects future mortality or heart failure (HF) in at-risk patients.
Incidence, Predictors and Outcomes of Non-Home Discharge Following Transcatheter Aortic Valve Implantation: A Multicentre Australian Experience – The NHD TAVI Study
The American Journal of Cardiology
APRIL 6, 2024
Publication date: Available online 5 April 2024 Source: The American Journal of Cardiology Author(s): Anant D Butala, Shane Nanayakkara, Rohan V Navani, Sonny Palmer, Samer Noaman, Kawa Haji, Nay M Htun, Antony S.
CRESCENT: Mandibular Advancement Noninferior to CPAP For Sleep Apnea
American College of Cardiology
APRIL 6, 2024
Mandibular advancement devices (MAD) are noninferior to continuous positive airway pressure (CPAP) for lowering mean arterial blood pressure (MABP) in patients with moderate-to-severe obstructive sleep apnea (OSA), according to results from the CRESCENT trial.
How to control high blood pressure without medications
All About Cardiovascular System and Disorders
APRIL 6, 2024
Just because you have been told that your blood pressure is above normal need not mean that you are tied up to medications lifelong. Changes in lifestyle can definitely bring down your blood pressure even without medications. In those already taking medications, the dose of medications can be brought down by important lifestyle changes. Some lucky ones may be able to stop medications as well.
Video: Day 1 — ACCess Points Daily Wrap Up | ACC.24
American College of Cardiology
APRIL 6, 2024
Drs. Kim Eagle, Dharam Kumbhani, Payal Kohli, and Ajay Kirtane debate and discuss the outcomes of the trials presented on day 1 at ACC.24 including AEGIS II (0:45), VICTORION-INITATE (2:36), RELIEVE-HF (5:27) and STEP-HFpEF Dm (8:42).
Echocardiogram in Mitral Valve Prolapse with Mitral Regurgitation (MVP, MR)
All About Cardiovascular System and Disorders
APRIL 6, 2024
Transcript of the video: Now we will discuss echocardiogram in mitral valve prolapse. It is a fairly common condition. But, even though mitral valve prolapse can be detected echocardiographically in many cases, there may not be significant regurgitation and symptoms in many of them. Many of them may have just echo diagnosis without other relevances.
ACC.24 Opening Showcase Presidential Address
American College of Cardiology
APRIL 6, 2024
SEVENTY-FIVE YEARS! Today, we stand at a remarkable milestone, commemorating the founding of the ACC. In 1949 during what is often called the "Golden Age of Cardiology," 13 pioneering cardiologists led by Dr. Franz Groedel and Dr. Bruno Kisch met in New York City and laid the foundation for a professional home for cardiovascular clinicians seeking the latest science, cutting-edge research, and transformative education.
STEP HFpEF DM: Semaglutide 2.4 mg Improves Functional Status, Symptoms in Patients with Diabetes, HFpEF
HCPLive
APRIL 6, 2024
The STEP HFpEF DM trial at ACC.24 shows significant improvements in symptoms among patients with obesity-related HFpEF and diabetes mellitus.
A Double-Blind, Randomized Placebo-Procedure-Controlled Trial of an Interatrial Shunt in Patients With HFrEF and HFpEF
American College of Cardiology
APRIL 6, 2024
The goal of the RELIEVE-HF trial was to evaluate an interatrial shunt compared with placebo-procedure among patients with symptomatic heart failure.
Science behind the Study: Shooting the Messenger to Treat Hypertriglyceridemia
The New England Journal of Medicine
APRIL 6, 2024
This editorial describes the science behind an antisense drug targeting APOC3 mRNA to treat hypertriglyceridemia.
TELE-ACS: Telemedicine Intervention Associated With Reduction in Hospital Readmission, ER Visits
American College of Cardiology
APRIL 6, 2024
A robust telemedicine intervention across six months following an acute coronary syndrome (ACS) was associated with a reduction in hospital readmission, emergency department (ED) visits, unplanned coronary revascularization and patient-reported symptoms.
Mechanical Circulatory Support in Cardiogenic Shock — Persistence and Progress
The New England Journal of Medicine
APRIL 6, 2024
Acute myocardial infarction–related cardiogenic shock (AMI-CS) is characterized by systemic hypoperfusion due to cardiomyocyte necrosis and ventricular dysfunction.1 Cardiogenic shock affects 5 to 10% of patients presenting with acute myocardial infarction, and more than half the patients with AMI-CS die during the index hospitalization.2 Prompt reperfusion.
RELIEVE-HF: Does Impact of Interatrial Shunting Differ By HF Type?
American College of Cardiology
APRIL 6, 2024
Patients with heart failure (HF) who had an interatrial shunt inserted did not see any significant benefits overall, compared with those who underwent a placebo procedure, after a median 22-month follow-up, but results suggest the benefits of an interatrial shunt may vary by HF type, according to results from the RELIEVE-HF study presented during a Late-Breaking Clinical Trial session at ACC.24.
Another Look at Hypothermia for Out-of-Hospital Nonshockable Cardiac Arrest
NEJM Journal Watch - Cardiology
APRIL 6, 2024
In a patient-level analysis of data from two recent trials, patients with out-of-hospital cardiac arrest and an initial nonshockable rhythm treated with hypothermia did not have increased survival or improved functional outcome compared with normothermia.
Celebrating Milestones in Advancing CV Care
American College of Cardiology
APRIL 6, 2024
The ACC isn't the only cardiovascular society celebrating a milestone anniversary in 2024. Both the American Heart Association (AHA) and Association of Black Cardiologists (ABC) are celebrating 100 years and 50 years, respectively, while the Irish Cardiac Society (IRC) is celebrating its own 75-year legacy.
Outcomes After Left Atrial Appendage Clip Placement During Cardiac Surgery: A Nationwide Analysis
The American Journal of Cardiology
APRIL 6, 2024
Publication date: Available online 5 April 2024 Source: The American Journal of Cardiology Author(s): Jean-Luc A. Maigrot, Aaron J. Weiss, Guangjin Zhou, Haley N. Jenkins, Siran M. Koroukian, Krish C. Dewan, Edward G.
Societies Unite to Request a New, Independent Board of CV Medicine
American College of Cardiology
APRIL 6, 2024
Attaining and sustaining clinical cardiovascular competence is fundamental to providing appropriate, high-value health care and is part of a clinician's ethical and professional duties. Cardiologists have a personal, professional, ethical and public responsibility to stay up to date in their areas of practice, starting with self-identifying their own knowledge gaps and closing them in a formative, constructive way.
Let's personalize your content